The Role of ctDNA and PBMC in Treatment of Biliary Tract Cancer

Sponsor
RenJi Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT02809898
Collaborator
Huadong Hospital (Other), Shanghai Changzheng Hospital (Other), Yangpu District Central Hospital Affiliated to Tongji University (Other)
30
4
53
7.5
0.1

Study Details

Study Description

Brief Summary

Our study aims to evaluate the role of ct-DNA and PBMC as biomarkers in the treatment of biliary tract cancer.

Condition or Disease Intervention/Treatment Phase
  • Procedure: surgery or biopsy

Detailed Description

Biliary cancer ranked fifth in all gastrointestinal malignant cancer. Epidemiological surveys showed a significant increasing trend in recent years. How can make an early diagnosis of bile duct cancer as well as prognostic evaluation and efficacy monitoring, has become the hotspot. "liquid biopsy", which is meant to detect cancers by sequencing the DNA in a few drops of a person's blood. It may detect cancers early, even before symptoms arise, when there is just a few cells in the blood circulation.

cf-DNA in cancer patients often bears similar genetic and epigenetic features to the related tumor DNA. There is evidence that some of the cf-DNA originates from tumoral tissue. This, and the fact that cf-DNA can easily be isolated from the circulation and other body fluids of patients, makes it a promising candidate as a non-invasive biomarker of cancer. And we call the cf-DNA of tumor as ct-DNA.

Peripheral blood mononuclear cells (PBMC) is any peripheral blood cell having a round nucleus. These cells can be extracted from whole blood using ficoll, a hydrophilic polysaccharide. PBMC contains genetic material of tumor and may be applied as a biomarker.

This study aims to evaluate the role of ct-DNA and PBMC as biomarkers in the treatment of biliary tract cancer.

Study Design

Study Type:
Observational
Anticipated Enrollment :
30 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
The Role of ctDNA and PBMC as Biomarkers in Diagnostic, Efficacy Monitoring and Prognostic Evaluation of Biliary Tract Cancer
Actual Study Start Date :
Jul 1, 2016
Anticipated Primary Completion Date :
Dec 1, 2020
Anticipated Study Completion Date :
Dec 1, 2020

Outcome Measures

Primary Outcome Measures

  1. Pathological diagnosis of gallbladder polyps (Cholesterol / Adenoma / Others) [intraoperative]

    Sensitivity and specificity

Secondary Outcome Measures

  1. Tumor status (worse/ maintain/ better) [3 years]

    the level of ct-DNA compared with the tumor burden

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with suspected biliary tract cancer

  • Age from 18 - 70 years

  • No serious organic and mental illness;

Exclusion Criteria:
  • Pregnancy

  • No pathologic result

  • Suffering other malignancies at the same time.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Huadong Hospital Shanghai China 200000
2 Shanghai Yangpu district central hospital Shanghai China 200000
3 Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai China
4 Shanghai Changzheng Hospital Shanghai China

Sponsors and Collaborators

  • RenJi Hospital
  • Huadong Hospital
  • Shanghai Changzheng Hospital
  • Yangpu District Central Hospital Affiliated to Tongji University

Investigators

  • Principal Investigator: Tao Chen, M.D., Department of Biliary-pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
RenJi Hospital
ClinicalTrials.gov Identifier:
NCT02809898
Other Study ID Numbers:
  • cfDNA-GCCC
First Posted:
Jun 22, 2016
Last Update Posted:
Oct 17, 2019
Last Verified:
Oct 1, 2019
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Keywords provided by RenJi Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 17, 2019